These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 23957964)

  • 1. 10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL).
    Eberhardt WE; Gauler TC; Lepechoux C; Stamatis G; Bildat S; Krbek T; Welter S; Grunenwald D; Fischer B; Rodrigo Hde L; Theegarten D; Le Chevalier T; Seeber S; Stuschke M; Poettgen C
    Lung Cancer; 2013 Oct; 82(1):83-9. PubMed ID: 23957964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
    Eberhardt WE; Pöttgen C; Gauler TC; Friedel G; Veit S; Heinrich V; Welter S; Budach W; Spengler W; Kimmich M; Fischer B; Schmidberger H; De Ruysscher D; Belka C; Cordes S; Hepp R; Lütke-Brintrup D; Lehmann N; Schuler M; Jöckel KH; Stamatis G; Stuschke M
    J Clin Oncol; 2015 Dec; 33(35):4194-201. PubMed ID: 26527789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accelerated hyperfractionated radiotherapy within trimodality therapy concepts for stage IIIA/B non-small cell lung cancer: Markedly higher rate of pathologic complete remissions than with conventional fractionation.
    Pöttgen C; Eberhardt W; Graupner B; Theegarten D; Gauler T; Freitag L; Abu Jawad J; Wohlschlaeger J; Welter S; Stamatis G; Stuschke M
    Eur J Cancer; 2013 Jun; 49(9):2107-15. PubMed ID: 23510803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensified high-dose chemoradiotherapy with induction chemotherapy in patients with locally advanced non-small-cell lung cancer-safety and toxicity results within a prospective trial.
    Pöttgen C; Eberhardt WE; Gauler T; Krbek T; Berkovic K; Jawad JA; Korfee S; Teschler H; Stamatis G; Stuschke M
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):809-15. PubMed ID: 19427744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study.
    Friedel G; Budach W; Dippon J; Spengler W; Eschmann SM; Pfannenberg C; Al-Kamash F; Walles T; Aebert H; Kyriss T; Veit S; Kimmich M; Bamberg M; Kohlhaeufl M; Steger V; Hehr T
    J Clin Oncol; 2010 Feb; 28(6):942-8. PubMed ID: 20100967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of trimodality therapy in patients with stage IIIA (N2-bulky) and stage IIIB non-small-cell lung cancer.
    Li J; Dai CH; Yu LC; Chen P; Li XQ; Shi SB; Wu JR
    Clin Lung Cancer; 2009 Sep; 10(5):353-9. PubMed ID: 19808194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction chemotherapy with triweekly docetaxel and cisplatin followed by concomitant chemoradiotherapy with or without surgery in stage III non-small-cell lung cancer: a phase II study.
    Aydiner A; Sen F; Saglam EK; Oral EN; Eralp Y; Tas F; Toker A; Dilege S
    Clin Lung Cancer; 2011 Sep; 12(5):286-92. PubMed ID: 21729649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: long-term results of a phase II trial.
    Eberhardt W; Stamatis G; Stuschke M; Wilke H; Müller MR; Kolks S; Flasshove M; Schütte J; Stahl M; Schlenger L; Budach V; Greschuchna D; Stüben G; Teschler H; Sack H; Seeber S
    Br J Cancer; 1999 Dec; 81(7):1206-12. PubMed ID: 10584883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twelve-year follow-up of trimodality therapy for stage IIIA non-small cell lung cancer.
    Weitberg AB; Liu L; Yashar J; Glicksman AS
    J Exp Clin Cancer Res; 2001 Sep; 20(3):335-40. PubMed ID: 11718211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb): a pilot phase I/II trial.
    Pöttgen C; Eberhardt W; Bildat S; Stüben G; Stamatis G; Hillejan L; Sohrab S; Teschler H; Seeber S; Sack H; Stuschke M
    Ann Oncol; 2002 Mar; 13(3):403-11. PubMed ID: 11996471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401.
    Takayama K; Inoue K; Tokunaga S; Matsumoto T; Oshima T; Kawasaki M; Imanaga T; Kuba M; Takeshita M; Harada T; Shioyama Y; Nakanishi Y
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1353-9. PubMed ID: 24166107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
    Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
    Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial.
    Eberhardt W; Wilke H; Stamatis G; Stuschke M; Harstrick A; Menker H; Krause B; Müeller MR; Stahl M; Flasshove M; Budach V; Greschuchna D; Konietzko N; Sack H; Seeber S
    J Clin Oncol; 1998 Feb; 16(2):622-34. PubMed ID: 9469351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.
    Albain KS; Rusch VW; Crowley JJ; Rice TW; Turrisi AT; Weick JK; Lonchyna VA; Presant CA; McKenna RJ; Gandara DR
    J Clin Oncol; 1995 Aug; 13(8):1880-92. PubMed ID: 7636530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.
    Davies AM; Chansky K; Lau DH; Leigh BR; Gaspar LE; Weiss GR; Wozniak AJ; Crowley JJ; Gandara DR;
    J Clin Oncol; 2006 Nov; 24(33):5242-6. PubMed ID: 17114656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
    Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
    J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term survival results for patients with locally advanced, initially unresectable non-small cell lung cancer treated with aggressive concurrent chemoradiation.
    Langer CJ; Curran WJ; Keller SM; Catalano RB; Litwin S; Blankstein KB; Haas N; Campli SN; Comis RL
    Cancer J Sci Am; 1996; 2(2):99-105. PubMed ID: 9166507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response.
    Pourel N; Santelmo N; Naafa N; Serre A; Hilgers W; Mineur L; Molinari N; Reboul F
    Eur J Cardiothorac Surg; 2008 May; 33(5):829-36. PubMed ID: 18367406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial.
    Rusch VW; Albain KS; Crowley JJ; Rice TW; Lonchyna V; McKenna R; Livingston RB; Griffin BR; Benfield JR
    J Thorac Cardiovasc Surg; 1993 Jan; 105(1):97-104; discussion 104-6. PubMed ID: 8380477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.